Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-02-26Clinical Trial Update: The Effects of DHA on Attention Deficit and Hyperactivity Disorder [Phase 3]
Phase 3 trial update on the effects of DHA in Attention Deficit Hyperactivity Disorder (ADHD).
-
FDA approval · 2020-02-25FDA Approved: STRATTERA — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for Strattera (atomoxetine hydrochloride) submitted by Eli Lilly and Company.
-
CLINICAL_TRIALS trial_result · 2020-02-05Clinical Trial Update: Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) [Phase 3]
Phase 3 safety and tolerability study of SHP465 in children 4-12 with ADHD; study terminated with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-01-29Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) [Phase 1]
Phase 1 trial assessing safety, tolerability, and pharmacokinetics of SHP465 in children aged 4 to 5 with ADHD; completed with results poste…
-
CLINICAL_TRIALS trial_result · 2020-01-18Clinical Trial Update: Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD) [Phase 3]
A Phase 3 clinical trial in preschool children aged 4-5 with ADHD has completed with results posted in 2020.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-01-18Clinical Trial Update: Dasotraline Pediatric Extension Study [Phase 3]
Phase 3 pediatric extension study of dasotraline for ADHD has completed; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-01-18Clinical Trial Update: Effects of Noise Cancelling Headphones on Neurocognitive and Academic Outcomes in ADHD [NA]
A completed clinical trial evaluating whether noise cancelling headphones affect neurocognitive and academic outcomes in ADHD, with results …
-
CLINICAL_TRIALS trial_result · 2020-01-14Clinical Trial Update: Predictive Executive Functioning Models Using Interactive Tangible-Graphical Interface Devices in Adults [NA]
Completed clinical trial evaluating predictive executive functioning models using interactive tangible-graphical interface devices in adults…
-
FDA approval · 2020-01-08FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for methylphenidate hydrochloride manufactured by Sun Pharmaceutical Industries, Inc. This actio…
-
CLINICAL_TRIALS trial_result · 2020-01-02Clinical Trial Update: Role of Coenzyme Q in ADHD in Children [Phase 3]
Phase 3 clinical trial investigating the role of Coenzyme Q in ADHD in children is currently recruiting.
-
FDA approval · 2019-12-27FDA Approved: INTUNIV — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for INTUNIV (guanfacine) by Takeda Pharmaceuticals America, Inc. The approval pertains to a modifica…
-
CLINICAL_TRIALS trial_result · 2019-12-26Clinical Trial Update: Lisdexamfetamine's Effect In ADHD in the Brain and Cognition [Phase 4]
Phase 4 trial update on lisdexamfetamine in ADHD; study terminated with results posted in 2019.
-
FDA approval · 2019-12-11FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Original Application (Elite Laboratories, Inc.)
The FDA approved Elite Laboratories' generic mixed amphetamine salts product under an original ANDA. The product contains four salt forms of…
-
CLINICAL_TRIALS trial_result · 2019-12-10Clinical Trial Update: PK/PD Pediatric ADHD Classroom Study [NA]
Clinical trial update of a PK/PD pediatric ADHD classroom study completed; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-12-05Clinical Trial Update: A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD) [Phase 1, Phase 2]
Clinical trial update for ND0801 in ADHD across Phase 1 and Phase 2, study is completed.
-
CLINICAL_TRIALS trial_result · 2019-12-03Clinical Trial Update: Bupropion for ADHD in Adolescents With Substance Use Disorder [Phase 4]
Phase 4 trial update on bupropion for adolescents with ADHD and substance use disorders, with results posted after completion.
-
CLINICAL_TRIALS trial_result · 2019-12-03Clinical Trial Update: Predictive Executive Functioning Models Using Interactive Tangible-Graphical Interface Devices [NA]
A completed clinical trial investigating predictive executive functioning models using interactive tangible-graphical interface devices for …
-
FDA approval · 2019-11-29FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for dexmethylphenidate hydrochloride (Teva Pharmaceuticals USA, Inc.). The decision updates the appr…
-
FDA approval · 2019-11-29FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Dexmethylphenidate hydrochloride by Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2019-11-29FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a supplemental application for Dexmethylphenidate hydrochloride from Amneal Pharmaceuticals of New York LLC, supporting the gen…
-
FDA approval · 2019-11-29FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved Sun Pharmaceutical's supplemental application to market a generic dexmethylphenidate hydrochloride product for attention-de…
-
FDA approval · 2019-11-29FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Cranbury Pharmaceuticals, LLC)
FDA approved a supplemental application for dexmethylphenidate hydrochloride from Cranbury Pharmaceuticals, LLC.
-
FDA approval · 2019-11-29FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Par Health USA, LLC)
FDA approved a supplemental application for Dexmethylphenidate hydrochloride, a generic ADHD medication, submitted by Par Health USA, LLC.
-
FDA approval · 2019-11-29FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a supplemental application for dexmethylphenidate hydrochloride from Amneal Pharmaceuticals of New York LLC.
-
FDA approval · 2019-11-29FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for dexmethylphenidate hydrochloride extended-release from Lannett, making the generic extended-rele…